YIF1B Inhibitors
Chemical inhibitors of YIF1B operate through various mechanisms to disrupt the protein's normal function in vesicular transport processes within the cell. Wortmannin and LY294002 are both phosphoinositide 3-kinase (PI3K) inhibitors. By impeding PI3K, these molecules indirectly interfere with intracellular signaling pathways crucial for protein trafficking, which is a key process involving YIF1B. Brefeldin A targets the ADP-ribosylation factor (ARF), leading to the inhibition of vesicle formation and transport between the endoplasmic reticulum (ER) and the Golgi apparatus, a pathway in which YIF1B is actively involved. Furthermore, Monensin, as an ionophore that disrupts ion gradients, can alter Golgi pH levels, thereby hindering the secretory pathway and indirectly impairing YIF1B's role in this process.
Additionally, Dynasore inhibits the GTPase dynamin, which is crucial for vesicle scission, potentially inhibiting YIF1B's function in the post-Golgi network. Nocodazole and Paclitaxel exert their effects through modulation of microtubules, with Nocodazole disrupting and Paclitaxel stabilizing these structures, thus interfering with microtubule-dependent vesicle transport, a process in which YIF1B plays a part. Latrunculin B and Cytochalasin D both act on the actin cytoskeleton, preventing its polymerization, which is necessary for vesicular trafficking and, by extension, YIF1B's function. Jasplakinolide, conversely, stabilizes actin filaments but also leads to the disruption of normal actin dynamics crucial for YIF1B's role. Endosidin2 affects endosomal trafficking, a complex process requiring YIF1B for proper vesicle sorting and delivery. Lastly, ML-9 targets kinase activity, specifically inhibiting myosin light-chain kinase (MLCK), which is important for vesicle movement, thus again potentially disrupting YIF1B's role in the secretory pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a steroidal metabolite of fungi that inhibits phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it can indirectly lead to the functional inhibition of YIF1B by disrupting intracellular signaling pathways necessary for protein trafficking, a process that YIF1B is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a synthetic molecule that also inhibits PI3K. Given that YIF1B is implicated in vesicular trafficking, the inhibition of PI3K by LY294002 could disrupt the membrane dynamics and trafficking routes necessary for YIF1B function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A is a lactone antibiotic that inhibits protein transport by interfering with the ADP-ribosylation factor (ARF), a small GTPase involved in vesicle budding. Since YIF1B is involved in vesicular transport, Brefeldin A's action can lead to an inhibition of YIF1B's role in transport between the ER and Golgi. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that disrupts intracellular ion gradients. It can inhibit the secretory pathway by altering Golgi pH levels. Since YIF1B is part of the protein trafficking machinery, Monensin can indirectly inhibit YIF1B by impairing secretion pathways it is involved with. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore is a small molecule that inhibits dynamin, a GTPase implicated in vesicle scission. As YIF1B is involved in trafficking, the inhibition of vesicle scission by Dynasore could inhibit YIF1B's function in the post-Golgi network. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole is a synthetic compound that disrupts microtubules. Since microtubules are necessary for vesicle transport, and YIF1B is involved in such transport, Nocodazole can inhibit YIF1B's function by destabilizing the microtubule network it relies on. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $229.00 | 29 | |
Latrunculin B binds to actin monomers and prevents polymerization. As actin dynamics are critical for vesicular trafficking, the inhibition of actin polymerization indirectly causes functional inhibition of YIF1B by disrupting the cytoskeletal organization required for its function. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and in doing so can disrupt normal cellular processes, including vesicular transport. The abnormal stabilization of microtubules can indirectly inhibit YIF1B by impairing its vesicle trafficking function. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $180.00 $299.00 | 59 | |
Jasplakinolide stabilizes actin filaments and can lead to the inhibition of YIF1B by disrupting normal actin dynamics, which are essential for YIF1B's role in vesicular trafficking. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $110.00 $440.00 $660.00 $1200.00 | 2 | |
ML-9 is a kinase inhibitor that can inhibit myosin light-chain kinase (MLCK). Given that MLCK activity affects vesicle movement, the inhibition of MLCK by ML-9 can lead to the functional inhibition of YIF1B by disrupting vesicle dynamics within the secretory pathway. | ||||||